Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3mfIlKSzVyPUCuNFYyKM7:TR?= M2\zVXNCVkeHUh?=
ALL-PO MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjUOm1KSzVyPUCuNFY{PTVizszN Moj0V2FPT0WU
697 NYfhPZZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEm5O|Yh|ryP NHXxRmhUSU6JRWK=
NCI-H748 M3fCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMUCzN|Qh|ryP MoDIV2FPT0WU
NKM-1 NFLsO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vQTGlEPTB;MD6xNFkyOiEQvF2= NVjJNW01W0GQR1XS
ES1 NIf5W4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly3TWM2OD1yLkGxNlU2KM7:TR?= MXjTRW5ITVJ?
NCI-H1963 NFfRN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[5TWM2OD1yLkGxOVc6KM7:TR?= M37BRXNCVkeHUh?=
NCI-H1417 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDEVnR{UUN3ME2wMlEzQTd2IN88US=> MmLOV2FPT0WU
NEC8 MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7pTm5kUUN3ME2wMlE{PTJ5IN88US=> MknpV2FPT0WU
CRO-AP2 NGPkOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\hTndKSzVyPUCuNVY5QDlizszN NXzBcW4yW0GQR1XS
A3-KAW NXfle5FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fmZ2lEPTB;MD6xO|YzPyEQvF2= NGjHbHZUSU6JRWK=
SF539 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonrTWM2OD1yLkG5OVk{KM7:TR?= M2HjUXNCVkeHUh?=
NOS-1 NX\rN2xKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMUm2NVkh|ryP NHH2d5BUSU6JRWK=
NTERA-S-cl-D1 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjIOXYxUUN3ME2wMlIxOTF|IN88US=> Mln6V2FPT0WU
COR-L88 NF7QO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTzd2ltUUN3ME2wMlIzQTV7IN88US=> MX;TRW5ITVJ?
EM-2 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDwXINKSzVyPUCuNlQxPzlizszN NVrhdohOW0GQR1XS
KARPAS-45 NYeyN5NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm4XY9KSzVyPUCuNlc5OzNizszN M1XYd3NCVkeHUh?=
DSH1 NHnMc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMki3NFgh|ryP NELMV5RUSU6JRWK=
HT-144 M1rlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwM{CyOVYh|ryP MkD6V2FPT0WU
ATN-1 M1X1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPnZmhuUUN3ME2wMlMxPTd4IN88US=> NVTs[poxW0GQR1XS
HEL M2OweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T5dGlEPTB;MD6zNVM1QCEQvF2= NXfNR|hsW0GQR1XS
NB12 NXSxPGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvrTWM2OD1yLkOxO|U3KM7:TR?= NVj3Zpo5W0GQR1XS
LU-139 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwM{O1NUDPxE1? M3znTnNCVkeHUh?=
J-RT3-T3-5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvZTWM2OD1yLkOzO|E3KM7:TR?= MYfTRW5ITVJ?
MOLT-13 M1HTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG2VWNPUUN3ME2wMlM{QDFizszN NEHX[VFUSU6JRWK=
SR M{X3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLnTWM2OD1yLkO0NlYyKM7:TR?= NYPZNpMzW0GQR1XS
CMK MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[2TWM2OD1yLkO1O|I4KM7:TR?= NYfSUXM2W0GQR1XS
ES8 NGHEUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jvRmlEPTB;MD6zOlAzOiEQvF2= MkjlV2FPT0WU
LB647-SCLC M4mwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HwZmlEPTB;MD6zOlc{KM7:TR?= MU\TRW5ITVJ?
TE-8 Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXwTWM2OD1yLkO2PVM2KM7:TR?= MVLTRW5ITVJ?
BV-173 NVTJR4ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:wTWM2OD1yLkO3NVIyKM7:TR?= M4[0V3NCVkeHUh?=
DEL NV\MNJFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\KTmlEPTB;MD6zO|Q5PyEQvF2= M4XVcHNCVkeHUh?=
ARH-77 M3\NeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvSTWM2OD1yLkO4NVk{KM7:TR?= MUPTRW5ITVJ?
NCCIT M1vlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjJTWM2OD1yLkO4OlQ6KM7:TR?= M1;zSXNCVkeHUh?=
RPMI-8402 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLOTWM2OD1yLkO4O|AyKM7:TR?= MmfaV2FPT0WU
MONO-MAC-6 NVLBO|ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13kWGlEPTB;MD6zPFc4PiEQvF2= M13jTXNCVkeHUh?=
SK-MM-2 NHL4RlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HOSWlEPTB;MD6zPVg3QCEQvF2= NVzBe2kzW0GQR1XS
CHP-126 NUPyOI1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwNECyN|Eh|ryP NHixbopUSU6JRWK=
A101D M3vFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXBTWM2OD1yLkSwN{DPxE1? NXK2V402W0GQR1XS
SCH MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwNECzOFIh|ryP MmDFV2FPT0WU
NMC-G1 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn64TWM2OD1yLkSwN|Y4KM7:TR?= M4XUO3NCVkeHUh?=
NCI-H209 MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrkTWM2OD1yLkSwOlE{KM7:TR?= NF:4VHBUSU6JRWK=
MOLT-16 NVvwUnpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXYZXZKSzVyPUCuOFExOTdizszN NY[z[JFyW0GQR1XS
RPMI-6666 MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PQXWlEPTB;MD60NVEzKM7:TR?= Mn;xV2FPT0WU
OPM-2 MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwNEG1NVMh|ryP MUPTRW5ITVJ?
MRK-nu-1 NXTwVXc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7rUGhKSzVyPUCuOFMyPTNizszN Mlu3V2FPT0WU
BC-1 NXjS[|V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jNfGlEPTB;MD60N|QxOyEQvF2= NHvOPIpUSU6JRWK=
MHH-NB-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfhW4ZYUUN3ME2wMlQ{PDV|IN88US=> NWLSRoQ4W0GQR1XS
Ramos-2G6-4C10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHRfnhKSzVyPUCuOFM5QTdizszN NIHNWVdUSU6JRWK=
LS-513 NITYWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq0TWM2OD1yLkS0OVAyKM7:TR?= MnjtV2FPT0WU
K5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwNEewNlUh|ryP NVLxOVUyW0GQR1XS
HOP-62 MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jrcGlEPTB;MD60PFM2QCEQvF2= MY\TRW5ITVJ?
NCI-H187 NYH2emt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XUN2lEPTB;MD60PVIzPyEQvF2= MXzTRW5ITVJ?
BE-13 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2noWWlEPTB;MD60PVY3OSEQvF2= NV;MZmJwW0GQR1XS
HC-1 NFXsOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jqfmlEPTB;MD61NFQ4OyEQvF2= MVXTRW5ITVJ?
ACN MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfX[3RKSzVyPUCuOVExOjhizszN NGDXU2RUSU6JRWK=
HCC1599 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDieVRKSzVyPUCuOVE2PyEQvF2= M2C5UHNCVkeHUh?=
MV-4-11 NV3KSIUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTzTWM2OD1yLkWzNFQyKM7:TR?= NYq1TJpwW0GQR1XS
LC-2-ad NU\VbVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwNUO2OlMh|ryP M1HWSHNCVkeHUh?=
HL-60 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fTc2lEPTB;MD61OFI3OSEQvF2= NXzuZYdvW0GQR1XS
NB17 M4jmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G4SGlEPTB;MD61OFM5KM7:TR?= NHz6XHdUSU6JRWK=
TE-1 NFPYN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmexTWM2OD1yLkW1N|A3KM7:TR?= NF7rV5dUSU6JRWK=
NCI-H524 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHoTWM2OD1yLkW1OFAyKM7:TR?= MnnOV2FPT0WU
MZ7-mel NGHBTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe0[mpPUUN3ME2wMlU3OTB3IN88US=> NETmcG9USU6JRWK=
L-363 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e5PWlEPTB;MD61OlY2PyEQvF2= NHfxfJRUSU6JRWK=
BL-41 NGexfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XXcGlEPTB;MD61Olg5QSEQvF2= M1q4d3NCVkeHUh?=
LU-134-A NYW2N41JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwNUewO|Mh|ryP Mo\KV2FPT0WU
SIG-M5 NWLZVppmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX76[YhsUUN3ME2wMlU4QDR6IN88US=> MkP4V2FPT0WU
ONS-76 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rZT2lEPTB;MD61PFI1OiEQvF2= Mm[0V2FPT0WU
KARPAS-299 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED4OHVKSzVyPUCuOVg2ODRizszN NITOT45USU6JRWK=
DU-4475 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXBTWM2OD1yLkW4O|A{KM7:TR?= MkPlV2FPT0WU
NB69 M{PYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwNUm4NlUh|ryP M1;PNnNCVkeHUh?=
MHH-PREB-1 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofyTWM2OD1yLk[wO|E6KM7:TR?= NYGxSZZrW0GQR1XS
LU-165 NGnobohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi2Z4JKSzVyPUCuOlE5OTJizszN M17Bc3NCVkeHUh?=
LOUCY NFHUdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXlTWM2OD1yLk[zN|Y1KM7:TR?= MX3TRW5ITVJ?
NCI-H526 M{Dtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwNkO1OFEh|ryP NUewR4xpW0GQR1XS
KE-37 NYXpR4NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PFN2lEPTB;MD62OFI4PiEQvF2= MmTtV2FPT0WU
NALM-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGwTWM2OD1yLk[0PFYh|ryP NGXZVVlUSU6JRWK=
CW-2 M2\KUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnh[4RKSzVyPUCuOlU4QTRizszN NEW4flhUSU6JRWK=
SU-DHL-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfLRYZKSzVyPUCuOlU6PDdizszN NFn6RmFUSU6JRWK=
NB13 NHXqeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLwd3lpUUN3ME2wMlY3QDF5IN88US=> M1\oVHNCVkeHUh?=
QIMR-WIL NHTkdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;WTWM2OD1yLk[4N|Q{KM7:TR?= Ml3tV2FPT0WU
ECC12 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXOTWM2OD1yLkewNFg3KM7:TR?= NV3QTVNJW0GQR1XS
KALS-1 NXfHbppJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SzfWlEPTB;MD63NFQ6OiEQvF2= MVjTRW5ITVJ?
COR-L279 NFP6Tm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7JRZVKSzVyPUCuO|A6QTZizszN MYTTRW5ITVJ?
NB14 NVrQVXJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwN{K2NVch|ryP MVHTRW5ITVJ?
CCRF-CEM M1fwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGyTWM2OD1yLke0OlYyKM7:TR?= MXPTRW5ITVJ?
SW954 M4jubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSwTWM2OD1yLke1PVk6KM7:TR?= M3Xhd3NCVkeHUh?=
IST-SL1 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwN{ezOFgh|ryP M4Dr[3NCVkeHUh?=
LAMA-84 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwN{e1Olch|ryP NF7aZnpUSU6JRWK=
Daudi M4ruR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M171SGlEPTB;MD63O|Y5OSEQvF2= Mle4V2FPT0WU
BC-3 M{C4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2xRYFKSzVyPUCuO|g{ODhizszN NIPBcVFUSU6JRWK=
HCC2998 M{SyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\YTWM2OD1yLke4N|Yh|ryP NVXjTG4{W0GQR1XS
NCI-H69 M3i4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfLTWM2OD1yLkiwNVQ4KM7:TR?= M4nvfXNCVkeHUh?=
CPC-N NV;YUGVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\MNGlEPTB;MD64NFUzPCEQvF2= MWLTRW5ITVJ?
NOMO-1 NHf4dVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG4W3Y6UUN3ME2wMlgyODh2IN88US=> M1n1TnNCVkeHUh?=
CESS NGHycoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fE[mlEPTB;MD64NVE6PyEQvF2= NEPMfHZUSU6JRWK=
LC4-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwOESwNFch|ryP NXvNflN{W0GQR1XS
BL-70 NH\jbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEmwWmNKSzVyPUCuPFU4ODJizszN NXj5[2U6W0GQR1XS
ES4 NEf6fYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrVSWN1UUN3ME2wMlg2QDZ6IN88US=> MXrTRW5ITVJ?
HCE-T Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoexTWM2OD1yLki3NVcyKM7:TR?= NH7YdnBUSU6JRWK=
JAR NHy0TWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojkTWM2OD1yLki3PFI4KM7:TR?= MnvmV2FPT0WU
ST486 M3TCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLGTWM2OD1yLki3PVE4KM7:TR?= MW\TRW5ITVJ?
KS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7wTWM2OD1yLki4NFk3KM7:TR?= MYDTRW5ITVJ?
GDM-1 NIXyT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHYTWM2OD1yLki4Olg4KM7:TR?= M4Pn[3NCVkeHUh?=
EHEB MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnIfHZKSzVyPUCuPVI2QDVizszN NYXZ[ZcyW0GQR1XS
LB2518-MEL MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW4d5pKSzVyPUCuPVMzQDRizszN MVPTRW5ITVJ?
GOTO NUfK[3d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwOUWwO|Yh|ryP MVXTRW5ITVJ?
LXF-289 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f6cGlEPTB;MD65OVkxOSEQvF2= M1:wTXNCVkeHUh?=
ES6 M2jnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PNXGlEPTB;MD65OlQ{PyEQvF2= NV3NSlB{W0GQR1XS
OS-RC-2 NWLOUHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwOU[4N{DPxE1? Mn6yV2FPT0WU
DMS-153 NXnLNHRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwOUe0Olkh|ryP MVvTRW5ITVJ?
SK-PN-DW Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfteXhKSzVyPUCuPVc5OzFizszN NYWzbnloW0GQR1XS
HH NYTxXHpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[4TWM2OD1yLkm4PVU6KM7:TR?= MXrTRW5ITVJ?
SH-4 NHrwTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PX[2lEPTB;MT6wNlQyKM7:TR?= MmP0V2FPT0WU
MOLT-4 NV73c3lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwMEO0OVQh|ryP NGe4PGhUSU6JRWK=
TGW M1f3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwMEe2O|Uh|ryP NULsfFVbW0GQR1XS
L-540 NFrhd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwMUC2NFQh|ryP NITVXIFUSU6JRWK=
PF-382 NFPlXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwMUG1NVMh|ryP NXzPWGFOW0GQR1XS
LC-1F NITzOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;LVW1KSzVyPUGuNVIxODdizszN MnXPV2FPT0WU
OVCAR-4 NHW5VWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILxPVNKSzVyPUGuNVMyPjVizszN NHG4dnlUSU6JRWK=
A4-Fuk NIfYXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\I[WJwUUN3ME2xMlE2OzZ2IN88US=> MWLTRW5ITVJ?
HCC2218 NUXrToR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jUSWlEPTB;MT6xOlY1OSEQvF2= M3zHZ3NCVkeHUh?=
HAL-01 M3fIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL0TWM2OD1zLkG2PVQ{KM7:TR?= M2O4cnNCVkeHUh?=
IST-MEL1 M4HVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwMUe2OVkh|ryP MnLBV2FPT0WU
NCI-H719 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwMUe4PVgh|ryP M3HBTXNCVkeHUh?=
EVSA-T NGrkfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrTNVBTUUN3ME2xMlE5OTF2IN88US=> Ml3sV2FPT0WU
SK-NEP-1 MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfjPG5rUUN3ME2xMlIxOjZ4IN88US=> NFG5UGdUSU6JRWK=
OCUB-M MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwMkG0PFkh|ryP MlvRV2FPT0WU
MEG-01 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwMkKxNVgh|ryP M3OzcnNCVkeHUh?=
no-10 NGXNSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwMkOxNVIh|ryP NYfiN2NlW0GQR1XS
MHH-CALL-2 NH32O4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW5TWM2OD1zLkK0O|IyKM7:TR?= M37XVHNCVkeHUh?=
SK-N-DZ Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwMkS3O|Yh|ryP NUnrcIFXW0GQR1XS
SCLC-21H Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP4dnNlUUN3ME2xMlI3PDd6IN88US=> MYjTRW5ITVJ?
CTV-1 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrRZVRKSzVyPUGuNlc1OjVizszN Mn;EV2FPT0WU
NB1 NFf1VpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz5WXNVUUN3ME2xMlI4PzN{IN88US=> NGrpNmhUSU6JRWK=
NCI-H64 NEG2U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:2TWM2OD1zLkK4OFYzKM7:TR?= MU\TRW5ITVJ?
MDA-MB-134-VI MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT6VmdKSzVyPUGuNlg2PzdizszN NGr1e|RUSU6JRWK=
LB2241-RCC NIDZSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjSe|hWUUN3ME2xMlI5PjZ|IN88US=> MWHTRW5ITVJ?
8-MG-BA NVK1T5Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7VToNKSzVyPUGuNlg5PjZizszN MlLWV2FPT0WU
LP-1 NIPuVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3RmlEPTB;MT6yPVk1PyEQvF2= NVL0N2xrW0GQR1XS
LS-411N NVfFSVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwM{C5PVgh|ryP MmHlV2FPT0WU
CAL-148 NELUUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHl[XpNUUN3ME2xMlMzPTR{IN88US=> NU\MfIFmW0GQR1XS
NCI-H2171 M4jYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nUOmlEPTB;MT6zOFUxOiEQvF2= MYXTRW5ITVJ?
JiyoyeP-2003 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C2VWlEPTB;MT6zOVM6KM7:TR?= MYrTRW5ITVJ?
NCI-H2107 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTLR5pVUUN3ME2xMlM2QDh|IN88US=> NIPjUpBUSU6JRWK=
BB30-HNC M2TsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PxZmlEPTB;MT6zPFk4QCEQvF2= M1j0ZnNCVkeHUh?=
K-562 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zvNWlEPTB;MT6zPVIyQSEQvF2= MmLpV2FPT0WU
PSN1 NUW3OnlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;4R2lEPTB;MT60NlI5PyEQvF2= M4D4[HNCVkeHUh?=
HCC2157 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{OxdWlEPTB;MT60NlY6OSEQvF2= MXPTRW5ITVJ?
SBC-1 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nSfGlEPTB;MT60Nlc1OSEQvF2= M{jMWnNCVkeHUh?=
MC116 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT3TWM2OD1zLkSzOlE2KM7:TR?= MlP1V2FPT0WU
KARPAS-422 NXPjNIx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHBZ4FKSzVyPUGuOFU{PThizszN NV;5eoJYW0GQR1XS
LB996-RCC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXlOHZKSzVyPUGuOFcyODNizszN MoHwV2FPT0WU
MSTO-211H NF3hW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XZb2lEPTB;MT60O|k5PyEQvF2= NU\aWoQzW0GQR1XS
BT-474 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\zTWM2OD1zLkWxO|Y1KM7:TR?= M4q2OnNCVkeHUh?=
A388 NWXBbnhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwNUG5OFUh|ryP Mmi3V2FPT0WU
SJSA-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\UT2lEPTB;MT61NlI3KM7:TR?= NYXn[Jd2W0GQR1XS
COLO-829 M1rDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH4TlhKSzVyPUGuOVM2PjRizszN MmfwV2FPT0WU
KM-H2 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwNU[2O{DPxE1? NGXIdFhUSU6JRWK=
GR-ST M1nqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjyTopMUUN3ME2xMlU3QDJizszN NH\WUI1USU6JRWK=
RPMI-8866 NVfTO5hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwNkCxOFQh|ryP M{\ofXNCVkeHUh?=
KG-1 NYe5cGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16wWGlEPTB;MT62NVkxOSEQvF2= MnvpV2FPT0WU
NCI-H82 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwNkO0NFYh|ryP M{jqWXNCVkeHUh?=
LB1047-RCC Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrseWxKSzVyPUGuOlM1PTlizszN MkjNV2FPT0WU
KM12 NYLhXHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwNkS3JO69VQ>? MWTTRW5ITVJ?
NB5 NUPj[GJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rQUGlEPTB;MT62OVY4PyEQvF2= MonMV2FPT0WU
HDLM-2 M1e0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr4XpVzUUN3ME2xMlY5OjhzIN88US=> M3fXOXNCVkeHUh?=
KU812 NXL3TmZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC5R5Y5UUN3ME2xMlY6PjB3IN88US=> NHXXNXlUSU6JRWK=
DB M2XRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[3TWM2OD1zLkewN|U{KM7:TR?= MmPDV2FPT0WU
HD-MY-Z NF7kPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHIfXVKSzVyPUGuO|UzOzRizszN MVvTRW5ITVJ?
KURAMOCHI MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LFbmlEPTB;MT63O|IxPyEQvF2= NX\XTmtoW0GQR1XS
ETK-1 NEj3TGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPVTWM2OD1zLke4PFc6KM7:TR?= NGmzSppUSU6JRWK=
SK-UT-1 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nHVWlEPTB;MT63PVM5QCEQvF2= MnuyV2FPT0WU
HUTU-80 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwN{m1NFgh|ryP M3rBcXNCVkeHUh?=
ES7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml33TWM2OD1zLkiwN|AzKM7:TR?= MmfaV2FPT0WU
SW872 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHTOJpSUUN3ME2xMlgyOzl3IN88US=> MVjTRW5ITVJ?
TK10 NWHVXm5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i1PGlEPTB;MT64N|ExQCEQvF2= MmDDV2FPT0WU
LB831-BLC M4CyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPVTWM2OD1zLkizOVY{KM7:TR?= NUjUcW1wW0GQR1XS
TE-9 M4rEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\lXWpUUUN3ME2xMlg1PDJ{IN88US=> Mm\1V2FPT0WU
MLMA M1HvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwOEiyN|Qh|ryP NVTzU5lKW0GQR1XS
D-542MG M2PSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrOOllKSzVyPUGuPFk{PzNizszN NFPCXmxUSU6JRWK=
EW-16 NGDmRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf3NnFKSzVyPUGuPVI4OiEQvF2= NVq4OXJkW0GQR1XS
LOXIMVI MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u4XWlEPTB;MT65N|I5KM7:TR?= NYPiU2F2W0GQR1XS
GB-1 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPTXnBvUUN3ME2xMlk{QDZ4IN88US=> NF;0OYNUSU6JRWK=
IST-SL2 NWLtZWZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDsTWM2OD1{LkCwNlYzKM7:TR?= Mo\LV2FPT0WU
LAN-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[4fFhGUUN3ME2yMlAyQTZ4IN88US=> NWH6O4VKW0GQR1XS
NCI-H510A M2rCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwMES1NFIh|ryP MVHTRW5ITVJ?
NCI-H1092 M4Lxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;yTWM2OD1{LkC1NVI1KM7:TR?= NVrrdnloW0GQR1XS
HT MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwMUC0OVQh|ryP M1XkVHNCVkeHUh?=
RL95-2 NVjCUYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PIVmlEPTB;Mj6xNVQ5OiEQvF2= MUDTRW5ITVJ?
NCI-H1355 NXXqPGVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfMbplKSzVyPUKuNVE4QTJizszN M160XnNCVkeHUh?=
NCI-H720 MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\QRY1KSzVyPUKuNVY5PzNizszN MlHMV2FPT0WU
NCI-H1522 NH\PcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnkc45LUUN3ME2yMlIyPzJ|IN88US=> M3flUnNCVkeHUh?=
LB373-MEL-D MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDKT25KSzVyPUKuNlY6ODJizszN M1TFRnNCVkeHUh?=
DG-75 M1PXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETZV5pKSzVyPUKuNlcyPDhizszN NGrRU41USU6JRWK=
ML-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:5NmlEPTB;Mj6zNlg2PSEQvF2= MkTpV2FPT0WU
SF126 NFTxW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW0TWM2OD1{LkOzNFk1KM7:TR?= NIfMelVUSU6JRWK=
MPP-89 M3rZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHNTWM2OD1{LkOzNVQ2KM7:TR?= NUTVbWhjW0GQR1XS
NCI-H345 M324Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJwM{OyO|ch|ryP M1rle3NCVkeHUh?=
LS-123 M3P3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X1TWlEPTB;Mj6zOFk{PiEQvF2= NXz2doZ2W0GQR1XS
NB10 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHIWWpUUUN3ME2yMlQyODl{IN88US=> MYrTRW5ITVJ?
CGTH-W-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJwNEKyOlch|ryP M4jwT3NCVkeHUh?=
CP66-MEL MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwNEe3O{DPxE1? M1fHSHNCVkeHUh?=
L-428 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni0TWM2OD1{LkS4OVIyKM7:TR?= M1u0cHNCVkeHUh?=
DMS-79 M1Ts[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLqWHhKSzVyPUKuOVQyODNizszN NV7BWWNHW0GQR1XS
NCI-H1882 M2LSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zncWlEPTB;Mj62O|U3OiEQvF2= MnnzV2FPT0WU
KGN M1zL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml64TWM2OD1{Lke2PFc3KM7:TR?= NInpN5ZUSU6JRWK=
EW-1 NV;mUXl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7oTWM2OD1{Lke3NFg{KM7:TR?= MYLTRW5ITVJ?
U-266 M2G5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj6TWM2OD1{Lki0PFI{KM7:TR?= M{PTXnNCVkeHUh?=
COLO-320-HSR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni0TWM2OD1{Lki1OlQyKM7:TR?= M{e5W3NCVkeHUh?=
KMOE-2 NUjLSZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF72emtKSzVyPUKuPFc4OTFizszN NGHRTotUSU6JRWK=
BB49-HNC MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\oTWM2OD1{LkmyOFgh|ryP MXPTRW5ITVJ?
GI-1 M1rkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJwOUK5OVch|ryP NHfRNY5USU6JRWK=
NCI-H1304 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFWzN4JKSzVyPUOuNFA2OTFizszN MVPTRW5ITVJ?
NCI-H2227 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNwMEKwO|kh|ryP MXHTRW5ITVJ?
U-87-MG NIS1W3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;kTWM2OD1|LkCzOVE{KM7:TR?= M1PvUnNCVkeHUh?=
NCI-H747 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;FTWM2OD1|LkC1NlA3KM7:TR?= MVzTRW5ITVJ?
CTB-1 NV\WOXhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwMEWzO|Yh|ryP MYPTRW5ITVJ?
RPMI-8226 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fKXGlEPTB;Mz6xOFM4QCEQvF2= NEnZVW5USU6JRWK=
NCI-H2141 NH\NcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHyeZJNUUN3ME2zMlE3PTZ4IN88US=> MoLJV2FPT0WU
IST-MES1 Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jTb2lEPTB;Mz6xPFI4QSEQvF2= MWTTRW5ITVJ?
TE-5 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfD[YZKSzVyPUOuNlE{PDJizszN MX\TRW5ITVJ?
UACC-257 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjHTWM2OD1|LkSzOlU6KM7:TR?= M175cXNCVkeHUh?=
SK-N-FI M1W0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\5TWM2OD1|LkS1NlI4KM7:TR?= MV;TRW5ITVJ?
MFH-ino NVLpS41FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KwdmlEPTB;Mz60OlU5QSEQvF2= MojuV2FPT0WU
SF268 NGGwZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXHWW9KSzVyPUOuOFgyPzRizszN MUfTRW5ITVJ?
TE-12 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPGVI5KSzVyPUOuOVE3QTlizszN NEHNV3lUSU6JRWK=
NB6 NWLNOZh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrCNmZKSzVyPUOuOVU2PjNizszN MmDBV2FPT0WU
DJM-1 NY\1VI04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13xPWlEPTB;Mz61PVg6QSEQvF2= MYjTRW5ITVJ?
MZ1-PC NEHYdlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjMTWM2OD1|Lk[xOlI1KM7:TR?= NHGzWGJUSU6JRWK=
OCI-AML2 NWfsTYtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTNwNkK2O|Eh|ryP NXfPOlVCW0GQR1XS
NCI-H1155 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLWNmdKSzVyPUOuO|A6PDdizszN NITvSFhUSU6JRWK=
RKO MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkThTWM2OD1|Lke3NVg6KM7:TR?= MnzwV2FPT0WU
ECC4 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfCR5EzUUN3ME2zMlk4OTl3IN88US=> MXfTRW5ITVJ?
BB65-RCC Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP1OJBQUUN3ME2zMlk4PTR5IN88US=> NFS5[XdUSU6JRWK=
EB-3 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr1TWM2OD1|Lkm5OlM{KM7:TR?= MWXTRW5ITVJ?
SHP-77 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjOTGlKSzVyPUSuNFA2OjRizszN NVLKWGpHW0GQR1XS
NCI-H2196 M2XoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV73NIhnUUN3ME20MlA2PjJ3IN88US=> Mo[wV2FPT0WU
GI-ME-N M3LrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXUPXhzUUN3ME20MlA3Ozl7IN88US=> Mn:wV2FPT0WU
MN-60 NXjSO5VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfjTWM2OD12LkGwPFch|ryP NFvuSGZUSU6JRWK=
NCI-H1694 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\uTWM2OD12LkGzOFA2KM7:TR?= MU\TRW5ITVJ?
LU-65 NI\jcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7PPZkxUUN3ME20MlE2OzN{IN88US=> M3z0UXNCVkeHUh?=
NCI-H1436 NHvCbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[1co5KSzVyPUSuNVg{OzNizszN NEjmb5dUSU6JRWK=
KINGS-1 M2DxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnBRVNKSzVyPUSuN|E1OzJizszN Mk\3V2FPT0WU
GT3TKB NH\QRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTtTWM2OD12LkOzNlY5KM7:TR?= MoiyV2FPT0WU
Becker M2fxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\QW|Q2UUN3ME20MlM4OzF{IN88US=> NEPvT|RUSU6JRWK=
HCC1187 M4LhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTRwOEm2OVch|ryP M4i0TXNCVkeHUh?=
D-502MG NWS1d4trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf4e|NKSzVyPUWuNFA1OTZizszN MnHVV2FPT0WU
VA-ES-BJ NG\zWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TLd2lEPTB;NT6xN|c4QCEQvF2= M{\ENnNCVkeHUh?=
NB7 NHvkUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL1TWM2OD13LkG0NVEzKM7:TR?= M2PvOHNCVkeHUh?=
SW962 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL0dGpKSzVyPUWuN|g5OTRizszN MXTTRW5ITVJ?
no-11 NYfmXI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\EZ5dKSzVyPUWuO|Y{PDNizszN MVXTRW5ITVJ?
KNS-81-FD M3;Jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXFW3RCUUN3ME21MlkxPjl2IN88US=> NWrlS4VyW0GQR1XS
COLO-684 NUjLV4NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDuTWM2OD13Lkm5OFk1KM7:TR?= NIjnPGVUSU6JRWK=
D-263MG NX7YcGtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjRZVE2UUN3ME22MlA5QDl3IN88US=> NH3XeW1USU6JRWK=
EW-24 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3yRZFKSzVyPU[uNlg2OSEQvF2= M1HYSnNCVkeHUh?=
TE-10 NG\FVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLPOFdKSzVyPU[uOFI3OjNizszN NWHWOVRIW0GQR1XS
EKVX MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\6ZmlEPTB;Nj60OlMzOSEQvF2= NIPVV2hUSU6JRWK=
NCI-H1648 NUnwTJdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XDdmlEPTB;Nj62O|U2PyEQvF2= MUnTRW5ITVJ?
LB771-HNC M{fXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjMTWM2OD14LkmyN|AyKM7:TR?= NF[zcWpUSU6JRWK=
SK-MEL-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRThwMUOxOlYh|ryP NInUfVFUSU6JRWK=
COLO-668 NH3PN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv5d3dKSzVyPUiuNlc4QDZizszN NUn4coxCW0GQR1XS
EW-12 NX;wb|RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7yUZJKSzVyPUiuOFA5ODNizszN NH76UJFUSU6JRWK=
A253 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XRSGlEPTB;OD64OFY3OSEQvF2= MX3TRW5ITVJ?
NCI-H2126 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\3eWdKSzVyPUiuPFk{OTlizszN NHSwPY1USU6JRWK=
Calu-6 M4PRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nxW2lEPTB;OD65PVA1OiEQvF2= M2PMPXNCVkeHUh?=
NCI-H23 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTlwMUe3OFYh|ryP NFn5PGlUSU6JRWK=
WSU-NHL MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLVTWM2OD17Lke3OFc5KM7:TR?= MVPTRW5ITVJ?
MMAC-SF MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHIO4hoUUN3ME25Mlk4QTB2IN88US=> MmPiV2FPT0WU
SK-LMS-1 NWPZWIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFyLkK4N|Qh|ryP Ml3MV2FPT0WU
GCIY NYHZVWVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPTc4tKSzVyPUGwMlU6OjRizszN M2HFfnNCVkeHUh?=
TE-15 NFPZVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLucnRKUUN3ME2xNU43ODB2IN88US=> MnvuV2FPT0WU
EoL-1-cell MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ETWM2OD1zMT63OlgzKM7:TR?= NILnUFJUSU6JRWK=
NCI-H2081 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTkWXZKSzVyPUGxMlc4QDZizszN M1\aVXNCVkeHUh?=
EW-3 M4nWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDOTWM2OD1zMj6yOFY{KM7:TR?= MWfTRW5ITVJ?
CAS-1 Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHnR2xKSzVyPUGyMlM3OzFizszN MnLyV2FPT0WU
C2BBe1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TTdGlEPTB;MUKuOlE{OSEQvF2= MWPTRW5ITVJ?
D-247MG M4\5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr3VnZYUUN3ME2xNk44QTV{IN88US=> MV7TRW5ITVJ?
NCI-SNU-5 NVjBclBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXP4UlloUUN3ME2xNk45ODF|IN88US=> NGCxTYFUSU6JRWK=
LS-1034 NU\PSHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnpPXZKSzVyPUG0MlM6PzVizszN NUPVeJllW0GQR1XS
EW-18 NYjYcpRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGwS3FpUUN3ME2xOE41PDhizszN NEnSVGFUSU6JRWK=
Raji NFTMSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLaTWM2OD1zND61NFQ6KM7:TR?= NXzq[JNRW0GQR1XS
D-283MED MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF2Lk[yO|Eh|ryP M4roUHNCVkeHUh?=
MZ2-MEL M4DiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\MXJJKSzVyPUG0Mlk3QTZizszN MVzTRW5ITVJ?
NCI-SNU-16 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF3LkS2N|Mh|ryP MWPTRW5ITVJ?
P30-OHK NV\VNYhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nqbGlEPTB;MUeuO|g{OSEQvF2= MneyV2FPT0WU
RXF393 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37j[GlEPTB;MUmuNFE5PiEQvF2= NFHqZ|BUSU6JRWK=
NCI-H1395 MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfxT2t1UUN3ME2yNE43PzB|IN88US=> M{XlSHNCVkeHUh?=
U-698-M MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL3W4JKSzVyPUKwMlcxPzVizszN MVfTRW5ITVJ?
NCI-SNU-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS0TWM2OD1{MD63NlI{KM7:TR?= MXnTRW5ITVJ?
SW684 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXY[I1kUUN3ME2yNU4yPzF4IN88US=> NUHXNGVpW0GQR1XS
NCI-H716 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJzLkOxOVQh|ryP NFLYfWdUSU6JRWK=
JVM-2 M4DiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj3eHdKSzVyPUKxMlQyOzNizszN M4TUNXNCVkeHUh?=
NCI-H1581 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvPbHVKSzVyPUKyMlQyPDhizszN NGLCU4RUSU6JRWK=
CA46 M33m[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjsRWtKSzVyPUOxMlY6OzZizszN MVnTRW5ITVJ?
SNB75 NYDGclhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzVTWM2OD1|Mz62OVA{KM7:TR?= MX3TRW5ITVJ?
KNS-42 M4XxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfVNoJKSzVyPUO1Mlk3OjRizszN Mlu1V2FPT0WU
TUR NE\uN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHFTWM2OD1|Nj6wOVIyKM7:TR?= M4jwOHNCVkeHUh?=
REH NIDmU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof6TWM2OD1|Nz64NlEyKM7:TR?= MknUV2FPT0WU
EW-22 NYXIbnhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M333WmlEPTB;NEKuNlg5PSEQvF2= NIrCeoVUSU6JRWK=
NCI-H446 NGWzdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTR{Lke4OVMh|ryP NXu1[XdiW0GQR1XS
ES3 NFnySWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR|LkGzN|kh|ryP M1LZV3NCVkeHUh?=
EW-11 NEnWZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L5O2lEPTB;NESuPFIyQCEQvF2= M4nyTnNCVkeHUh?=
RH-1 NVfZe2plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFewbWNKSzVyPUS3MlU5OTJizszN NYPubnB6W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID